Exhibit 99.1 Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of$26.4 million for the first quarter, reflecting 52% year-over-year growth Continued momentum across therapeutics platform with regulatory submissions for zoliflodacin and commercial launch of ZEVTERA (ceftobiprole) progressing as planned BURLINGAME, Cal ...